Login to Your Account

Octimet closes $12M series A round for oral Met inhibitor

By Cormac Sheridan
Staff Writer

Thursday, January 19, 2017

DUBLIN – Octimet Oncology NV raised €11.3 million (US$12 million) in a series A round for clinical development of a drug that hits c-Met, a receptor tyrosine kinase that is one of the most beguiling targets in cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription